Proof (Boston) stock

Private-market facts for current and former Proof (Boston) employees researching their stock.

Latest Round
Not disclosed
Valuation
Not publicly disclosed
Founded
Unknown
Headquarters
Boston, MA
Status
private

Talk to a Proof (Boston) stock specialist

Get personalized guidance on your Proof (Boston) shares — including current market activity, pricing context, and liquidity options.

Speak with an expert

Overview

Proof is a technology company based in Boston focused on network security and identity verification solutions.

Proof (Boston) outlook

Equity outlook100% data confidence
1x
Base scenario
3x
Upside scenario

For employees evaluating Proof (Boston) equity, a 1x base multiple suggests the stock may be close to fairly valued at current prices. The upside scenario at 3x is relatively close to the base case, suggesting more predictable but narrower range of outcomes.

These estimates reflect modeled return scenarios, not guaranteed outcomes. Actual results depend on company performance, market conditions, share class, and timing.

Illustrative model · v1.0.0 · Not investment advice

Selling Proof (Boston) shares

Why shareholders consider selling

Shareholders in Proof (Boston) may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Proof (Boston) does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.

Can you sell Proof (Boston) stock?

Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Enterprise Software sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Proof (Boston) shares would be outlined in the holder's equity agreement or the company's governing documents.

What affects the value of Proof (Boston) shares?

The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Enterprise Software market conditions, and any recent private-market transaction activity.

What should holders check before selling

  • The type of security held (common shares, preferred, options, RSUs)
  • Whether the equity is fully vested and, for options, whether it has been exercised
  • Any transfer restrictions, lock-up provisions, or company approval requirements
  • Estimated net proceeds after applicable taxes and transaction fees
  • Whether partial liquidity — selling a portion rather than the full position — may be a better fit

Tools for Proof (Boston) shareholders

Exploring equity in Proof (Boston) often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.

Latest funding round

Proof (Boston)'s latest funding details have not been publicly disclosed.

Industry

Similar private companies

Latest Proof (Boston) news

Trogenix announces publication of breakthrough pre-clinical data in Nature demonstrating complete tumour eradication and durable protection in aggressive brain cancer model
A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in 83% of treated cases with no toxicity over 11 months and no tumour recurrence in a brain cancer model that closely mimics human glioblastomaProvides compelling proof-of-concept for Trogenix's dual-payload gene therapy platform that combines direct tumour killing with immune activation to create durable protection against aggressive brain cancersPublished pre-clinical data underpins the Company’s transition to a clinical-stage oncology company, with patient dosing in its first clinical trial for glioblastoma expected in Q2 2026Edinburgh, UK, 08 April 2026 - Trogenix Ltd ('Trogenix”), a pioneering biotech company dedicated to developing innovative cancer therapies today announces the publication of its breakthrough pre-clinical data in Nature reporting complete tumour eradication and durable protection in a state-of-the-art aggressive brain cancer model that closely mimics human glioblastoma (GBM). The research supports an innovative approach to potentially achieving curative responses with long-term immunological protection against GBM, the most lethal form of brain cancer. It underpins the Company’s transition to a clinical-stage oncology company, with patient dosing in its first clinical trial for glioblastoma expected in Q2 2026.
The Manila TimesApr 9, 2026
KuCoin Introduces PROOF, a Trading Competition Focused on Verifiability and Fair Play
**media[1002176]**PROVIDENCIALES, Turks and Caicos Islands, April 6, 2026 /PRNewswire/ -- KuCoin, a leading global crypto platform built on trust, today announced the launch of KuCoin PROOF, one of KuCoin's biggest trading competitions to date, built around the core message 'Trade. Compete. Prove.' At a time when users are placing greater emphasis on fairness in trading activities, KuCoin PROOF is designed to introduce a more structured, verifiable, and accountable competition framework, where participation rules, performance measurement, and reward distribution are clear and consistent. Launching with a reward pool of up to 500K, KuCoin PROOF combines spot and futures competitions, individual and team battle modes, and a more structured campaign framework designed to support broader participation across KuCoin users, crypto traders, communities, and ecosystem participants. Additional campaign phases and themed competitions are expected to roll out in the coming months, further expanding the PROOF experience across formats and audiences.**media[1002177]**
The Manila TimesApr 6, 2026
Colorado court orders resentencing for former county clerk in election fraud scheme
A Colorado appeals court has ruled that a former county clerk convicted in a scheme that attempted to find proof of fraud in the 2020 presidential election should be resentenced. Tina Peters is serving a nine-year prison term after being convicted of state crimes for sneaking in an outside computer expert to make a copy of her county’s election computer system during a software update in 2021. Judges on the Colorado Court of Appeals said Thursday that a judge should not have considered Peters’ continued promotion of election fraud conspiracies when he sentenced her in 2024. The court sent Peters’ case back to a lower court for a judge to issue a new sentence.
The Atlanta Journal-ConstitutionApr 2, 2026

Talk to a Proof (Boston) stock specialist

Get personalized guidance on your Proof (Boston) shares — including current market activity, pricing context, and liquidity options.

Speak with an expert

Frequently asked questions

Is Proof (Boston) still a private company?
Yes, Proof (Boston) is currently a private company.
What is Proof (Boston)'s latest funding round?
The latest funding round has not been publicly disclosed.
What is Proof (Boston)'s valuation?
Proof (Boston)'s valuation has not been publicly disclosed.
Who are the investors in Proof (Boston)?
Investor information is not currently available.
Can I sell my Proof (Boston) stock?
Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Proof (Boston) stock can help you evaluate your options.

Related pages

Last verified: 2026-04-13 · Proof (Boston) data compiled from corporate filings, and public records.

Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.